Celltrion Healthcare’s Humira Biosimilar Wins EU Approval

February 18, 2021

The European Commission granted Celltrion Healthcare a marketing authorization for Yuflyma (CT-P17), a high-concentration biosimilar of AbbVie’s blockbuster Humira (adalimumab), for treating 13 chronic inflammatory diseases.

Although the commission has previously authorized Humira biosimilars, Yuflyma’s citrate-free formulation will give patients less pain when administered, giving it an edge over competitors, the company said.

The authorized indications include rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease and ulcerative colitis.

View today's stories